CTLA4 and hypophysitis: The time to develop IR-hypophysitis seems to be shorter after anti-CTLA-4 mono- or combination therapy when compared to anti-PD-(L)1 monotherapy (median 10.6 and 13.9 versus 21.9 weeks, respectively), as was shown previously for other irAEs (16).